small molecule

YOSPRALA

ASPIRIN; OMEPRAZOLE

Loss of exclusivityMarch 2033latest FDA-listed patent expiry
CompanyGENUS LIFE SCIENCES INC

Drug detail

Brand nameYOSPRALA
Active ingredientASPIRIN; OMEPRAZOLE
Strength81MG;40MG
Dosage formTABLET, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2016
Marketing statusDISCN

Listed patents

PatentExpiresType
9539214March 2033use U-1902
9987231January 2033use U-2324

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

YOSPRALA patent cliff — loss of exclusivity March 2033 | CliffBio